Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» TSRX's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TSRX Guru Trades in

TSRX Guru Trades in

Q2 2013

TSRX Guru Trades in Q2 2013

Jim Simons 65,061 sh (New)
Jean-Marie Eveillard 1,672,487 sh (-6.81%)
» More
Q3 2013

TSRX Guru Trades in Q3 2013

Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TSRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 Sold Out 0.04%$8.19 - $14.1 $ 13.6410%0
Jean-Marie Eveillard 2013-03-31 Add 69.6%0.02%$4.78 - $7 $ 13.64141%1794780
Jean-Marie Eveillard 2012-06-30 Add 102.26%0.01%$5.02 - $5.99 $ 13.64160%1058212
Jean-Marie Eveillard 2012-03-31 New Buy0.01%$4.8 - $6.78 $ 13.64168%523186
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )



Valuation & Return


Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:TEU.Germany,
Trius Therapeutics, Inc., was incorporated in California in June 2004. It is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company is developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, the company is discovering antibiotics for infections caused by Gram-negative bacteria using its structure based discovery platform. In December 2011, it reported top line data from its first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI. All primary and secondary endpoints for the ESTABLISH 1 study were achieved. In December 2012, the company completed enrollment in its second Phase 3 clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI. Its current development efforts are focused on developing tedizolid phosphate (formerly known as torezolid phosphate), an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. Its strategy is to discover and develop a pipeline of antibiotics focused on the treatment of life-threatening infections, consisting of tedizolid phosphate and additional compounds discovered internally using its proprietary discovery platform. The Company employs the services of Albany Molecular Research Incorporated to produce tedizolid phosphate API and Patheon, Inc., or Patheon, to produce the solid oral and sterile IV tedizolid phosphate finished products. It currently employs internal resources and third-party consultants to manage its manufacturing contractors. Its competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent it choose to sell any products outside of the United States.
» More Articles for TSRX


Articles On GuruFocus.com
comment on TSRX Mar 15 2013 
comment on TSRX Mar 15 2013 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial